	US 12,215,135 B2
	PDL2 compounds
Mads Hald Andersen, Naerum (DK)
Assigned to IO Biotech ApS, Copenhagen (DK)
Filed by IO BIOTECH APS, Copenhagen (DK)
Filed on Aug. 11, 2022, as Appl. No. 17/819,280.
Application 17/819,280 is a division of application No. 16/911,996, filed on Jun. 25, 2020, granted, now 11,447,537.
Application 16/911,996 is a division of application No. 16/344,445, abandoned, previously published as PCT/EP2017/076179, filed on Oct. 13, 2017.
Claims priority of application No. 16195949 (EP), filed on Oct. 27, 2016.
Prior Publication US 2023/0227529 A1, Jul. 20, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 14/70532 (2013.01) [A61K 39/39 (2013.01); A61K 39/4611 (2023.05); A61K 39/464411 (2023.05); A61P 35/00 (2018.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01)]

18 Claims

1. A vaccine composition comprising

a peptide, or a pharmaceutically acceptable salt thereof, wherein the peptide is an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO: 1, and consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO: 1, comprises an amino acid sequence selected from SEQ ID NOs: 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO: 1; and

an adjuvant.